Klohs W D, Steinkampf R W
Department of Chemotherapy, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105.
Cancer Res. 1988 Jun 1;48(11):3025-30.
The insensitivity of colon tumors to various anticancer agents was studied in vitro. The activity of Adriamycin (ADR) in several colon tumor cell lines was potentiated by the calcium channel blocker verapamil (VER). In the HCT-8 human colon adenocarcinoma cell line, VER potentiation of the activities of ADR and the anthrapyrazole CI-937 appeared to be related to its ability to enhance the net accumulation of both drugs and inhibit their efflux. VER, which potentiated ADR activity in HCT-8 cells by 4-fold, caused a 3.5-fold stimulation of ADR accumulation and 3.5-fold inhibition of ADR efflux, when compared to non-VER-treated cells. The low level of VER potentiation of CI-937 activity in HCT-8 cells (1.4-fold) was also reflected in CI-937 transport studies which demonstrated a 1.5-fold enhancement of CI-937 accumulation and a 1.4-fold inhibition of its efflux. VER was also found to stimulate ADR activity and accumulation in a normal small intestinal crypt cell line (IEC-6). The mechanism of drug efflux was examined in HCT-8 cells. Agents known to increase the permeability of the plasma membrane did not alter ADR accumulation or its efflux in HCT-8 cells unless these same agents were also capable of interacting with the lysosome. Tween 80 and the lysosomotropic detergent Triton WR-1339 as well as proton ionophores and lysosomotropic amines all stimulated ADR uptake and/or inhibited its efflux from HCT-8 cells. ADR efflux was also partially blocked by cytochalasin B. Based on these observations, we suggest that at least part of the inherent drug resistance of colon tumor cells results from the retention of an enhanced drug efflux mechanism which is found in normal intestinal epithelium where this property may provide protection from plant alkaloids and other xenobiotic agents ingested in the diet. The mechanism of this drug efflux from HCT-8 cells may involve drug partitioning into acidic vesicles within the cell and their subsequent release from these cells by exocytosis.
对结肠肿瘤对各种抗癌药物的不敏感性进行了体外研究。钙通道阻滞剂维拉帕米(VER)增强了阿霉素(ADR)在几种结肠肿瘤细胞系中的活性。在HCT-8人结肠腺癌细胞系中,VER对ADR和蒽吡唑CI-937活性的增强作用似乎与其增强两种药物的净积累并抑制其外排的能力有关。与未用VER处理的细胞相比,VER使HCT-8细胞中ADR活性增强了4倍,导致ADR积累增加了3.5倍,ADR外排抑制了3.5倍。VER对HCT-8细胞中CI-937活性的低水平增强作用(1.4倍)也反映在CI-937转运研究中,该研究表明CI-937积累增加了1.5倍,其外排抑制了1.4倍。还发现VER刺激正常小肠隐窝细胞系(IEC-6)中的ADR活性和积累。在HCT-8细胞中研究了药物外排的机制。已知增加质膜通透性的试剂不会改变HCT-8细胞中ADR的积累或其外排,除非这些试剂也能够与溶酶体相互作用。吐温80和溶酶体促透剂曲拉通WR-1339以及质子离子载体和溶酶体促透胺均刺激ADR摄取和/或抑制其从HCT-8细胞中外排。细胞松弛素B也部分阻断了ADR外排。基于这些观察结果,我们认为结肠肿瘤细胞固有的耐药性至少部分源于保留了增强的药物外排机制,这种机制存在于正常肠上皮中,在那里这种特性可能提供对饮食中摄入的植物生物碱和其他异源生物制剂的保护。HCT-8细胞中这种药物外排的机制可能涉及药物在细胞内分配到酸性囊泡中,随后通过胞吐作用从这些细胞中释放出来。